Immunome IMNM Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $11.72M-8.7% | $12.84M+371% | $2.72M+54,380% | $5K+150% | ||
| $6.94M-23.2% | $9.04M-35.5% | $14.02M— | —— | ||
| $177.29M+36.9% | $129.54M+461% | $23.09M-0.8% | $23.27M+64.9% | ||
| $43.77M+32.8% | $32.96M+67.7% | $19.66M+44.2% | $13.63M+22.9% | ||
| $231.05M-26.6% | $314.84M+155% | $123.55M+235% | $36.9M+46.4% | ||
| -$224.11M+26.7% | -$305.8M-179% | -$109.53M-197% | -$36.9M-46.4% | ||
| -3,228.8%+154pp | -3,382.4%-2,601pp | -781.4%— | —— | ||
| -$212.39M+27.5% | -$292.96M-174% | -$106.81M-189% | -$36.9M-49.3% | ||
| -3,060%+180pp | -3,240.4%-2,478pp | -761.9%— | —— | ||
| -$2.42+53.2% | -$5.17+4.1% | -$5.39-74.4% | -$3.09-45.1% | ||
| -$221.65M+27.1% | -$304.23M-179% | -$109.07M-199% | -$36.48M-49.2% | ||
| -3,193.3%+172pp | -3,365%-2,587pp | -778.1%— | —— | ||
| -$224.11M+26.7% | -$305.8M-179% | -$109.53M-197% | -$36.9M-46.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Immunome's income statement data come from?
- Every line is extracted from Immunome's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.